Ekso Bionics (NASDAQ:EKSO) Stock Price Passes Above Fifty Day Moving Average – Here’s Why

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $10.16 and traded as high as $10.90. Ekso Bionics shares last traded at $10.15, with a volume of 44,832 shares traded.

Analyst Ratings Changes

Several equities analysts have weighed in on EKSO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. Finally, Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Ekso Bionics currently has an average rating of “Reduce” and a consensus target price of $6.00.

Ekso Bionics Trading Down 6.9%

The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 0.09. The firm has a market cap of $36.13 million, a price-to-earnings ratio of -1.98 and a beta of 0.79. The business has a 50 day moving average of $10.16 and a 200 day moving average of $7.02.

Insiders Place Their Bets

In other Ekso Bionics news, major shareholder Daniel Asher purchased 15,540 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was bought at an average cost of $12.30 per share, for a total transaction of $191,142.00. Following the acquisition, the insider owned 270,432 shares of the company’s stock, valued at approximately $3,326,313.60. The trade was a 6.10% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On Ekso Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares during the period. Virtu Financial LLC acquired a new position in shares of Ekso Bionics during the 3rd quarter valued at about $57,000. Shay Capital LLC purchased a new position in shares of Ekso Bionics during the 3rd quarter worth about $67,000. Citadel Advisors LLC acquired a new stake in shares of Ekso Bionics in the third quarter worth approximately $198,000. Finally, Consolidated Portfolio Review Corp acquired a new stake in shares of Ekso Bionics in the third quarter worth approximately $333,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.